retatrutide mechanism triple agonist gip glp-1 glucagon retatrutide 40mg Retatrutide vs Semaglutide: Triple vs

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect

Aims/hypothesis Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) in individuals taking liraglutide and semaglutide

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

pooling data for lixisenatide (Adlyxin, Sanofi), liraglutide (Victoza,

ICD-10 codes to identify the outcome are included in supplementary table S1

and is not a GLP-1 agonist drug.**